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Summary
Characterized by proximal muscle weakness and wast-
ing, limb-girdle muscular dystrophies (LGMDs) are a
heterogeneous group of clinical disorders. Previous re-
ports have documented either autosomal dominant or
autosomal recessive modes of inheritance, with genetic
linkage studies providing evidence for the existence of
at least 12 distinct loci. Gene products have been iden-
tified for five genes responsible for autosomal recessive
forms of the disorder. We performed a genome scan us-
ing pooled DNA from a large Hutterite kindred in which
the affected members display a mild form of autosomal
recessive LGMD. A total of 200 markers were used to
screen pools of DNA from patients and their siblings.
Linkage between the LGMD locus and D9S302 (max-
imum LOD score 5.99 at recombination fraction .03)
was established. Since this marker resides within the
chromosomal region known to harbor the gene causing
Fukuyama congenital muscular dystrophy (FCMD), we
expanded our investigations, to include additionalmark-
ers in chromosome region 9q31-q34.1. Haplotype anal-
ysis revealed five recombinations that place the LGMD
locus distal to the FCMD locus. The LGMD locus maps
close toD9S934 (maximummultipoint LOD score 7.61)
in a region that is estimated to be ∼4.4 Mb (Genetic
Location Database composite map). On the basis of an
inferred ancestral recombination, the gene may lie in a
300-kb region between D9S302 and D9S934. Our re-
sults provide compelling evidence that yet another gene
is involved in LGMD; we suggest that it be named
“LGMD2H.”
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Introduction
The limb-girdle muscular dystrophies (LGMDs) repre-
sent a clinically and genetically heterogeneous group of
disorders with dominant and recessive inheritance. Seven
genes (LGMD2A–LGMD2G) encoding autosomal re-
cessive forms of the disorder have now been localized
(Bashir et al. 1994; Roberds et al. 1994; Bo¨nnemann et
al. 1995; Lim et al. 1995; Noguchi et al. 1995; Richard
et al. 1995; Nigro et al. 1996; Passos-Bueno et al. 1996;
Moreira et al. 1997), and, on the basis of the exclusion
of currently known loci, at least one more is postulated
to exist (Moreira et al. 1997; Weiler et al. 1997). Gene
products have been identified for five of the autosomal
recessive LGMDs; they are calpain 3 (LGMD2A) (Rich-
ard et al. 1995), and four members of the dystrophin-
associated protein complex (Straub and Campbell
1997)—g-sarcoglycan, a-sarcoglycan, b-sarcoglycan,
and d-sarcoglycan (LGMD2C–2F, respectively) (Rob-
erds et al. 1994; Lim et al. 1995; Noguchi et al. 1995;
Bo¨nnemann et al. 1996; Nigro et al. 1996; Passos-Bueno
et al. 1996). In addition, at least four autosomal dom-
inant LGMDs exist; four have been mapped (Speer et
al. 1992; McNally et al. 1997; Messina et al. 1997; van
der Kooi et al. 1997; Minetti et al. 1998), and genetic
exclusion studies suggest that others may exist (Speer et
al. 1995; van der Kooi et al. 1997). LGMDs are char-
acterized clinically by progressive muscle weakness and
wasting and, histopathologically, by muscle-cell changes,
including variation in fiber size, degeneration, necrosis,
regeneration, and fibrosis. Typically, the first muscles af-
fected are those of the shoulder and pelvic girdles, al-
though other muscle groups also can be affected. Facial
muscles, however, generally are spared. The different
forms of LGMD differ markedly in age at onset, rate of
progression, degree of muscle involvement, and clinical
severity (Bushby 1995).
We have been studying a relatively mild form of au-
tosomal recessive LGMD (MIM 254110), commonly
seen in Manitoba Hutterites, that first was described by
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Shokeir and Kobrinsky in 1976 (Shokeir and Kobrinsky
1976). Recently, we excluded all the known LGMD loci,
as well as other candidate genes encoding proteins of
the dystrophin-associated protein complex, as causing
LGMD in Hutterites and postulated that another gene
is responsible for this disorder (Weiler et al. 1997). In
the current study, a genome scan was performed on two
pools of DNA (patients and sibs) to search for the disease
locus. We subsequently mapped the gene for LGMD in
Hutterites, a gene that we have designated “LGMD2H,”
to a small part of chromosome region 9q31-q33, by
linkage and haplotype analysis.
Subjects and Methods
Subjects
The study included four related nuclear families of
Hutterite descent (A–D), comprising 40 individuals, all
of whom agreed to participate. Individuals were deemed
to be affected with LGMD if they (1) showed signs and
symptoms of proximal muscle weakness and had crea-
tine kinase (CK) levels more than four times the upper
limit of normal, in the absence of any other explanation
for CK elevation; (2) showed signs and symptoms of
proximal muscle weakness and had either an electro-
myogram or a muscle biopsy consistent with a my-
opathic disorder; or (3) showed extremely elevated CK
levels (x15 times the upper limit of normal) but were
asymptomatic. A muscle biopsy was considered to be
consistent with a myopathic disorder if it showed myo-
pathic changes consisting of abnormal variation in fiber
size, muscle-fiber degeneration or necrosis with phago-
cytosis, fiber splitting, internal nuclei, variable degrees
of fatty infiltration of the perimysium or endomysium,
and endomysial fibrosis. Individuals were considered to
be unaffected if they were asymptomatic, had a normal
CK level (in females, 28–116 U/liter; in males 52–175
U/liter), and, on the basis of manual muscle testing, had
normal muscle bulk, tone, and strength. Individuals were
assigned an unknown phenotype if they were asymp-
tomatic and their CK levels were greater than normal
but less than four times the upper limit of normal. A
total of 18 individuals (11 males and 7 females) were
classified as LGMD patients (fig. 1). Six individuals did
not meet the criteria as affected or unaffected. Four in-
dividuals (I-2, age 60 years; II-17, age 36 years; II-21,
age 29 years; and II-28, age 32 years) were asympto-
matic, with normal muscle strength, on the basis of man-
ual muscle testing, but had mildly elevated serum CK
levels less than four times the upper limit of normal.
Two individuals (II-23, age 50 years; and II-30, age 26
years) were asymptomatic on the basis of history and
provided DNA samples but were not available for either
physical examination or CK testing. The phenotypes of
these six individuals were classified as unknown. Clinical
data are summarized in table 1.
DNA Analysis
Genomic DNA was extracted from whole blood, ac-
cording to the method described by Greenberg et al.
(1987) or Zelinski (1991). Oligonucleotide primers de-
signed to amplify microsatellites were obtained from Re-
search Genetics. DNA samples were genotyped by use
of protocols reported by Sirugo et al. (1992) and Rodius
et al. (1994), with slight amendments.
Genome Scan, DNA Pooling, and Fine Mapping
Genealogical studies of these families (Weiler et al.
1997) suggested that the gene in all patients was identical
by descent. We therefore chose to perform a genome
scan using a DNA-pooling strategy (Sheffield et al. 1994;
Carmi et al. 1995). We pooled 400-ng samples of DNA
from each of nine confirmed affected individuals (II-1,
II-6, II-16, II-18, II-20, II-24, II-25, II-26, and II-27) into
one tube. We also pooled 400-ng samples of DNA from
each of the sibs of these patients (II-3, II-4, II-5, II-7, II-
17, II-19, II-21, II-22, II-23, II-28, II-29, and II-30) into
a second tube, which also contained DNA from two
other sibs in family D (not shown in fig. 1). These two
individuals were not genotyped for all markers, because
of the limited quantities of DNA. The phenotype of in-
dividuals II-7, II-17, II-21, II-23, II-28, and II-30 was
unknown at the time of DNA pooling, and, therefore,
DNA from these individuals was aliquotted into the sib-
DNA pool. Each pool was diluted to a concentration of
40 ng/ml. Samples of DNA (40-ng) from each of the two
DNA pools were genotyped with 200 microsatellite
markers (Research Genetics Set 5a, supplemented with
46 additional markers) spaced ∼20 cM apart. On visual
inspection, markers that showed a tendency to fewer
bands in the patient pool in comparison with the sib
pool were then used to genotype the individual family
members indicated in figure 1. Genotypes were obtained
for 11 markers in the region of D9S302, the marker,
from the genome scan, that showed significant linkage
to LGMD2H.
Linkage Analysis
Data from microsatellite typing of individual family
members were analyzed by use of the LINKAGE pro-
grams (version 5.2) (Lathrop and Lalouel 1984; Lathrop
et al. 1984, 1986) and the FASTLINK version (4.0P) of
the LINKAGE programs (Cottingham et al. 1993; Scha¨f-
fer et al. 1994; Scha¨ffer 1996; Becker et al. 1998).
MLINK was used for two-point linkage analysis, and
ILINK was used to obtain the maximum-likelihood es-
timate of the recombination fraction (v) under the as-
sumption of an autosomal recessive trait with complete
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Figure 1 Haplotypes in four Hutterite LGMD families. Affected individuals are represented by blackened diamonds; unaffected individuals
are represented by unblackened diamonds; and individuals with an unknown phenotype are denoted by a question mark within in a diamond.
Inferred genotypes are indicated by square brackets. Blackened haplotypes are those harboring the disease gene; unblackened haplotypes are
those that do not carry the disease gene; and gray shading indicates intervals of recombination. The coefficients of kinship between the spouses
in family A, family B, family C, and family D are .017, .065, .045, and .059, respectively; and the closest cousin relationships are third cousins
once removed in three ways, second cousins in two ways, second cousins, and half–first cousins once removed, respectively. The inbreeding
coefficient of parent I-3, who is affected, is .052, and the closest cousin relationship between the parents of I-3 is first cousins once removed
(Weiler et al. 1997).
penetrance. Disease-allele frequency was estimated to be
.05 (Weiler et al. 1997). Marker-allele frequencies were
calculated from the eight parents of the four nuclear
families. Multipoint LOD scores were computed at 0.1-
cM increments throughout the intervalD9S127–D9S60,
by use of the GENEHUNTER program (version 1.1)
(Kruglyak et al. 1996). The map order and inter-
marker distances used were D9S127–0.8 cM–D9S306–
1.2 cM–D9S2105–0.2 cM–D9S2107–0.3 cM–D9S172–
5.6 cM–D9S58–4.8 cM–D9S930–1.3 cM–D9S51–2.2
cM–D9S302–0.3 cM–D9S934–4.1 cM–D9S1850–3.1
cM–D9S60 (fig. 2). Intermarker distances for D9S127,
D9S306, and D9S2105 were based on physical mapping
data (Miyake et al. 1997); those for D9S2105,
D9S2107, and D9S172 were estimates based on linkage
disequilibrium (Toda et al. 1996) and an arbitrary as-
sumption that FCMD is ∼20 kb centromeric to
D9S2107; and those for D9S172–D9S60 were obtained
from the chromosome 9 summary map of the Genetic
Location Database (Collins et al. 1996). One centimor-
gan was assumed to be equivalent to 1 Mb. Both mul-
tipoint analysis of three markers (D9S302, D9S934, and
D9S1850) in the region of the highest LOD scores, on
the basis of the LINKMAP program in the FASTLINK
version of the LINKAGE programs, and multipoint anal-
ysis of eight markers (D9S172–D9S60), on the basis of
the VITESSE program (O’Connell and Weeks 1995),
gave similar results to those produced by the GENE-
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Figure 2 Multipoint LOD score of location of LGMD2H, for
the four pedigrees shown in fig. 1; LOD scores !4 are not shown.
Marker positions are indicated by vertical tick marks on the X-axis.
The total distance between D9S127 and D9S60 was estimated to be
∼23.9 cM. FCMD is estimated to be ∼20 kb from D9S2107 (Toda et
al. 1996).
Table 1
Summary of Clinical Data of Subjects with LGMD
Symptomatic (N) Asymptomatic (N)
Subjects (from fig. 1) I-3, II-1, II-2, II-6, II-10, II-11, II-12, II-15, II-16, II-18, II-20, II-24, II-25, II-26, II-
27 (15)
II-7, II-13, II-14 (3)
Age at onset (years) 8–27 (15) N/A
Age at presentation (years) 21–53 (15) N/A
Presenting symptoms Proximal weakness (9), back or neck pain (6), fatigue (4), waddling gait (2), mus-
cle wasting and weakness (1), wasting of shoulder girdle (1), difficulty climbing
stairs (1), weak legs (1)
N/A
CK (U/liter)a 250–3,130 U/liter (15) 2,740–4,280 U/liter (3)
Muscle biopsy Dystrophic (5) Dystrophic (1)
Electromyogram Myopathic (7), myopathic/neurogenic (1) None tested
Status in 1997 Ambulatory at age 23–39 years (11), ambulatory with difficulty at age 37–46 years
(3), wheelchair bound at age 61 years (1)
Asymptomatic at age
23–26 years (3)
SOURCE.—Weiler et al. (1997); authors’ unpublished data.
a Highest recorded values; normal range for females is 28–116 U/liter, and that for males is 52–175 U/liter.
HUNTER program (data not shown). Haplotypes were
constructed with a minimal number of recombinations,
under the assumption that no marker mutations had
occurred. A small number of missing genotypes were
inferred, where possible.
Results
Genome Scan Using a DNA-Pooling Strategy
Previous genealogical analysis of Hutterite families
with LGMD showed that this autosomal recessive dis-
ease could be traced back to x10 ancestors born in the
1700s, which suggested that all affected individuals
might be homozygous by descent, at the disease locus
(Weiler et al. 1997). We therefore initiated a genome
scan, using a DNA-pooling strategy with two pools: a
patient pool containing DNA from nine affected indi-
viduals, and a control pool comprising DNA from 14
sibs of patients. Of the 200 markers that were tested, 5
(D1S236, D6S259, D6S1003, D9S302, and D17S849)
gave a banding pattern suggestive of excess homozy-
gosity in the patients’ DNA pool compared with the sibs’
DNA pool (fig. 3). These markers were then used to
genotype individual family members, as shown in figure
1. Two-point linkage analysis was done. D9S302, lo-
cated in chromosome region 9q31-q33, showed signif-
icant linkage to LGMD2H, with a maximum LOD score
(Zmax) of 5.99 at a maximum v ( ) of .03.ˆv
Linkage and Haplotype Analysis
LGMD2H was linked to D9S302, which is estimated
to be 11 Mb from FCMD (Collins et al. 1996). It is
possible, therefore, that the loci for LGMD2H and
FCMD are the same. To obtain evidence that these dis-
ease loci are distinguishable, family members were geno-
typed for six markers known to be linked to FCMD
(D9S127, D9S306, D9S2105, D9S2107, D9S172, and
D9S58) (Toda et al. 1993, 1994, 1996). Two-point link-
age analysis of LGMD2H versus markers D9S127 and
D9S2107 (located, respectively, ∼2 Mb centromeric and
∼20 kb telomeric of FCMD) showed significantly neg-
ative LOD scores, of 5.17 and 4.03, respectively, at
(table 2). One of the markers linked to FCMDv  .01
(D9S306) showed significant linkage to the disease gene
( at ). However, recombinants betweenˆZ  3.15 v  0max
D9S2107, the marker closest to FCMD, and LGMD2H
were apparent in individuals II-8, II-11, II-13, II-27, and
II-29.
Five additional markers surrounding D9S302 and
telomeric to FCMD (D9S930, D9S51, D9S934,
D9S1850, and D9S60) were also used to genotype all
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Figure 3 Autoradiogram of two pools of DNA genotyped with
either D3S3038 or D9S302. Banding patterns are indicative of an
unlinked marker (D3S3038) and a linked marker (D9S302).
Table 2
LOD Scores for Linkage between LGMD2H and Markers in
Chromosome Region 9q31-q34.1
MARKER
LOD SCORE AT v 
ˆv Zmax.00 .01 .05 .10 .20 .30
D9S127  5.17 1.39 .10 .60 .51 .23 .62
D9S306 3.15 3.09 2.82 2.48 1.74 .98 .00 3.15
D9S2105  .37 .20 .34 .33 .20 .14 .36
D9S2107  4.03 1.46 .54 .06 .14 .28 .14
D9S172 1.58 1.55 1.42 1.26 .89 .51 .00 1.58
D9S58  .26 1.47 1.89 1.75 1.14 .13 1.93
D9S930  2.63 3.56 3.56 2.85 1.78 .07 3.62
D9S51 2.21 2.17 2.00 1.77 1.26 .72 .00 2.21
D9S302  5.80 5.92 5.46 4.12 2.52 .03 5.99
D9S934 5.97 5.86 5.40 4.81 3.53 2.14 .00 5.97
D9S1850  1.54 2.01 2.01 1.66 1.10 .07 2.04
D9S60  5.25 2.57 1.51 .61 .22 .50 .00
individuals in figure 1. Two-point analysis of LGMD2H
versus D9S930, D9S302, and D9S934 yielded LOD
scores 13.0 (table 2). D9S60, located ∼7.2 Mb telomeric
to D9S934 (Collins et al. 1996), showed a significantly
negative LOD score, 5.25, at . A distal recom-v  .01
bination is evident between D9S934 and D9S1850 in
individual II-16. Taken together, the proximal and distal
recombinations narrow the candidate region, which is
flanked by D9S302 and D9S1850 and containsD9S934,
to ∼4.4 Mb (3.9 cM in males, 6.2 cM in females) (Collins
et al. 1996). An estimate of the minimum candidate in-
terval defined by recombinant haplotypes in affected in-
dividuals (II-16 and II-27) is 7.9 Mb (5.9 cM in males,
10.0 cM in females), flanked by D9S930 and D9S1850
(Collins et al. 1996).
Figure 2 shows the multipoint LOD scores computed,
at 0.1-cM increments, by use of the GENEHUNTER
program. The multipoint analysis excludes LGMD2H
from being linked to a 5-cM region encompassing
FCMD (LOD scores !2) and indicates that the most
likely location of LGMD2H is close to D9S934. The
multipoint Zmax was 7.61 at D9S934; the 3-unit–LOD-
score support interval (Terwilliger and Ott 1994) ex-
tends from slightly distal to D9S302 to slightly proximal
to D9S1850, a region estimated to be ∼4.4 Mb.
Discussion
This study of a large extended Hutterite kindred has
led to the localization of yet another gene causing
LGMD. Because the Hutterite population is a genetic
isolate and because the parents of the four families in
our study are related (ranging from first cousins once
removed to half–third cousins once removed), we as-
sumed that the disease alleles were identical by descent
(Weiler et al. 1997). Under this assumption, we were
able to use a DNA-pooling strategy to perform an ef-
ficient genome scan. This resulted in linkage being de-
tected between LGMD2H and D9S302.
The cytogenetic location of D9S302 in chromosome
region 9q31-q33 agrees with that reported for FCMD
(Toda et al. 1993). FCMD is a severe congenital mus-
cular dystrophy associated with mental retardation, al-
though considerable heterogeneity has been reported
(Kondo-Iida et al. 1997). The form of LGMD in the
Hutterite kindred described in the present report also
exhibits clinical heterogeneity (Weiler et al. 1997). How-
ever, we have strong evidence that excludes FCMD as a
candidate gene for LGMD2H, on the basis of a signif-
icantly negative LOD score with D9S2107, a marker
estimated to be ∼20 kb from FCMD (Toda et al. 1996).
Furthermore, five recombinations were observed be-
tween this marker and LGMD2H. Multipoint analysis
excludes LGMD2H from being linked to a 5-cM region
encompassing FCMD. Two-point LOD scores 13.0 were
obtained for D9S930, D9S302, and D9S934, all located
telomeric to FCMD (Collins et al. 1996). Proximal and
distal recombination events are evident in individuals II-
29 and II-16, which narrows the candidate region within
the ∼4.4-Mb region bounded by D9S302 and D9S1850
(Collins et al. 1996). The multipoint analysis indicates
that the most likely location of LGMD2H is close to
D9S934 (multipoint Zmax  7.61).
Seven of the nine disease chromosomes among the
parents of the four sibships carry the same D9S51-
D9S302-D9S934-D9S1850 haplotype (151-266-222-
224 bp). If we assume that the haplotype (151-266-218-
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228) carried by parent I-6 resulted from an ancestral
recombination, then LGMD2H must be proximal to
D9S934. Furthermore, if we assume complete pene-
trance, the recombinant event in individual II-29 places
LGMD2H distal to D9S302. Thus, LGMD2H may lie
within a 0.3-Mb region between D9S302 and D9S934
(Collins et al. 1996). Finally, the 270-bp allele of
D9S302 on the disease haplotype carried by parent I-4
differs from that of the common disease-associated allele
(266 bp) at this locus. However, the alleles of the two
flanking markers are the same as those on the disease-
associated haplotype. This suggests that a mutation of
the tetranucleotide repeat,D9S302, has occurred (Weber
and Wong 1993). It is therefore likely that all of the
parents share the same LGMD2H mutation identical by
descent.
More than 40 genes have been mapped to chromo-
some region 9q31-q33, the region harboringLGMD2H.
After inspection of the map location, expression pattern,
and function of these genes, none appears to be a con-
vincing candidate gene. Hexabrachion, although located
centromeric to our candidate region (Collins et al. 1996),
has been detected in the muscles of Duchenne muscular
dystrophy patients (Mayer et al. 1997). Since it may be
implicated in the disorder described here, we will be
examining this possibility. Additionally, two mouse phe-
notypes—muscular dystrophy with myositis (Muller-
Seitz et al. 1993) and vacillans (Sirlin 1956, 1957; Mar-
bois et al. 1994)—that map to mouse chromosome
regions that are homologous to the LGMD2H candidate
region have been described. Further analysis of new pa-
tients, especially in the other two subdivisions of the
Hutterite population (Fujiwara et al. 1989), should al-
low us to narrow the region sufficiently for positional
cloning or identification of the gene on the basis of
mapped expressed sequences and known genes (Schuler
et al. 1996).
We have provided evidence for the location of a gene
for autosomal recessive LGMD in chromosome region
9q31-q33 in the Hutterites. There was no recombination
with D9S934, a marker in a region flanked by D9S302
and D9S1850 and estimated to be ∼4.4 Mb. Haplotype
analysis identified a putative ancestral recombination
that would further narrow the candidate region, to
∼300 kb.
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